The late-breaking clinical trials at the American College of Cardiology (ACC) 2015 annual meeting will include the latest data on outcomes for transcatheter aortic valve repair (TAVR), transcatheter mitral valve repair (TMRV), the use of computed tomography (CT) angiography to evaluate chest pain, first report on the use of TAVR embolic protection, denervation for pulmonary arterial hypertension, new antiplatelet/anticoagulation therapies and outcomes with drug-eluting stents versus bypass surgery.
ACC.15 will include five late-breaking clinical trial sessions and two featured clinical research sessions. There will be a late-breaking clinical trial deep dive session, where attendees can find out what it all means.
ACC.15 Opening Showcase and the Joint ACC/JACC Late-Breaking Clinical Trials
Session 400
Saturday, March 14, 8 – 10 a.m.
ACC.15 Main Tent (Hall H)
Joint American College of Cardiology/Journal of the American Medical Association Late-Breaking Clinical Trials
Session 402
Sunday, March 15, 8 – 9:15 a.m.
ACC.15 Main Tent (Hall H)
• Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes (OSLER-1 and -2)
• The EMBRACE STEMI Study: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Bendavia on Reperfusion Injury in Patients Treated with Standard Therapy Including Primary PCI and Stenting for ST-segment Elevation Myocardial Infarction (EMBRACE STEMI)
• Economic Comparison of Anatomic Versus Functional Diagnostic Testing Strategies in Symptomatic Patients with Suspected CAD: Results from the PROspective Multicenter Imaging Study for Evaluation of chest pain (PROMISE) Trial
Late-Breaking Clinical Trials III
Session 404
Sunday, March 15, 10:45 a.m. – noon
ACC.15 Main Tent (Hall H)
Featured Clinical Research Session I
Session 406
Sunday, March 15, 12:30 – 1:45 p.m.
Room 9
• Ulnar Artery Intervention Non-inferior To Radial Approach: A Reality Or Myth. AJmer ULnar ARtery (AJULAR) Working Group Study
• Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 5-Year Results of the PRECOMBAT Study
• Dual-antiplatelet Therapy Beyond One Year in Patients Receiving Coronary Stents For Treatment of Acute Coronary Syndrome: Analysis from the Dual Antiplatelet Therapy Study
• Perioperative Results And Complications in 15,964 Transcatheter Aortic Valve Implantations From The German Gary Registry
Joint American College of Cardiology/New England Journal of Medicine Late-Breaking Clinical Trials
Session 408
Monday, March 16, 8 – 9:15 a.m.
ACC.15 Main Tent (Hall H)
• Ablation vs. Amiodarone for Treatment of Persistent Atrial Fibrillation in Patients With Congestive Heart Failure and an Implanted device: Results from the AATAC Multicenter Randomized Trial
• Effectiveness of Surgical Ablation of Atrial Fibrillation during Mitral Valve Surgery: A Randomized Clinical Trial from the Cardiothoracic Surgical Trials Network
• Long-Term Effect of Goal Directed Weight Management on an Atrial Fibrillation Cohort: A 5-Year Follow-Up Study (LEGACY Study)
• Everolimus-Eluting Stents versus Bypass Surgery for Multivessel Coronary Artery Disease (BEST)
• Effect of Remote Ischemic Preconditioning on Clinical Outcomes in Patients Undergoing Coronary Artery Bypass Graft Surgery: A Multi-Center Randomized Controlled Clinical Trial (ERRICA)
Late-Breaking Clinical Trials V: TCT@ACC-i2 Interventional Cardiology
Session 410
Monday, March 16, 10:45 a.m. – noon
ACC.15 Main Tent (Hall H)
• The Total Trial: A Randomized Trial Of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone In Patients With St-elevation Myocardial Infarction Undergoing Primary PCI
• Transradial Versus Transfemoral Access In Patients With Acute Coronary Syndromes Undergoing Invasive Management: Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation Of Angiox (matrix) Access Site Program
• Bivalirudin Infusion Compared to Unfractionated Heparin In Patients With Acute Coronary Syndromes Undergoing Invasive Management: Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation Of Angiox (matrix) Anti-thrombin Program
• The Third DANish Study of Optimal Acute Treatment of Patients with ST-segment Elevation Myocardial Infarction: PRImary PCI in MULTIvessel Disease
• After Eighty Study
LBCT Deep Dive
Session 412
Monday, March 16, 12:30 – 1:45 p.m.
ACC.15 Main Tent (Hall H)
• Hear key highlights of the late-breaker clinical trials presented throughout ACC.15 and learn about what it means for physicians and their patients.
Featured Clinical Research Session II
Session 414
Monday, March 16, 12:30 – 1:45 p.m.
Room 6E
• Reduction in Total (First and Recurrent) Cardiovascular Events with Ezetimibe/Simvastatin Compared with Simvastatin Alone post Acute Coronary Syndromes in the IMPROVE-IT Trial
• A Prospective Comparison of Algisyl-LVR with Standard Medical Therapy to Determine Impact on Functional Capacity and Clinical Outcomes in Patients with Advanced Heart Failure (AUGMENT-HF Trial)
• Effects of Selective Serotonin Re-Uptake Inhibition on Mortality, Morbidity and Mood in Depressed Heart Failure Patients
• Baroreflex Activation Therapy for the Treatment of Heart Failure with a Reduced Ejection Fraction
• Pulmonary Artery Denervation For Treatment Of Pulmonary Arterial Hypertension: Results from a controlled before and after study
For more information: http://accscientificsession.acc.org/ACC.aspx
August 14, 2024 
